G3 Study Fully Enrolled Ahead of Schedule
Thursday, May 29, 2014
Global Genomics Group (G3), has completed the enrollment of patients in its international, prospective GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) study, months ahead of schedule. The study enrolled 7,500 patients at 48 clinical sites in North America, Europe, and Australia. GLOBAL is the first pan-omic study designed to identify disease-related pathways, new drug targets and biomarkers for cardiovascular diseases such as atherosclerosis.
"The early completion of the GLOBAL study is a significant milestone for G3 and confirms the strong support and interest from the medical community," said Tonya Mallory, chief executive officer, president and co-founder of Health Diagnostic Laboratory, a strategic partner of G3.
"G3 is in the process of analyzing the initial data and could have pilot data results as early as the first half of 2015. The study will analyze 22 trillion data points from 7,500 patients and will enable us to gain an in-depth understanding of the biological basis behind the complex processes responsible for atherosclerosis, leading to the identification of new biomarkers for early detection and new targets for the development of novel and effective drugs. As of today, only 20 drug candidates are being developed for atherosclerosis and coronary artery disease, the leading cause of death worldwide."
John Lesser, M.D., one of the principal investigators for the GLOBAL study and former president of the Society of Cardiovascular Computed Tomography, said, "Early disease detection and intervention, as well as effective therapeutic options, remain significant unmet medical needs in cardiovascular disease. It is quite remarkable to see such a large scale, comprehensive study executed so quickly. I am thrilled to be a part of this work, and I am looking forward to the potential of using the clinical diagnostic tests that result."